Danaher (NYSE:DHR) Shares Unloaded Rep. Julie Johnson

Representative Julie Johnson (D-Texas) recently sold shares of Danaher Co. (NYSE:DHR). In a filing disclosed on February 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Danaher stock on January 15th. The trade occurred in the Representative’s “MERRILL LYNCH TAX EFFICIENT CORE” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Dell Technologies (NYSE:DELL) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of ALLETE (NYSE:ALE) on 1/28/2025.
• Sold $1,001 – $15,000 in shares of PPG Industries (NYSE:PPG) on 1/27/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Chubb (NYSE:CB) on 1/24/2025.
• Sold $1,001 – $15,000 in shares of Morgan Stanley (NYSE:MS) on 1/24/2025.
• Purchased $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/17/2025.

Danaher Trading Up 1.5 %

Danaher stock opened at $206.66 on Friday. The business has a 50-day simple moving average of $230.00 and a two-hundred day simple moving average of $249.96. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. The company has a market cap of $149.26 billion, a P/E ratio of 39.14, a P/E/G ratio of 2.68 and a beta of 0.83. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the prior year, the business posted $2.09 earnings per share. Analysts predict that Danaher Co. will post 7.67 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were paid a dividend of $0.27 per share. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.52%. Danaher’s dividend payout ratio is currently 20.45%.

Insider Transactions at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on DHR shares. UBS Group decreased their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Scotiabank initiated coverage on shares of Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. Raymond James restated a “market perform” rating on shares of Danaher in a research report on Monday, February 3rd. Citigroup lowered their target price on shares of Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research note on Thursday, January 30th. Finally, Jefferies Financial Group lowered their target price on shares of Danaher from $285.00 to $260.00 and set a “buy” rating on the stock in a research note on Wednesday, January 29th. Seven equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $278.00.

Institutional Trading of Danaher

Hedge funds have recently made changes to their positions in the business. Norges Bank bought a new stake in shares of Danaher in the 4th quarter valued at approximately $2,130,740,000. FMR LLC lifted its position in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after buying an additional 3,217,631 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Danaher in the fourth quarter worth $391,172,000. Capital World Investors lifted its position in Danaher by 32.7% in the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate’s stock worth $1,460,215,000 after buying an additional 1,566,658 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Danaher by 14.3% in the fourth quarter. Northern Trust Corp now owns 7,934,991 shares of the conglomerate’s stock worth $1,821,477,000 after buying an additional 992,594 shares during the last quarter. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.